articleThe Lancet Diabetes & EndocrinologyJul 29, 2024Closed access

Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial

Aarhus University Hospital · Steno Diabetes Center · +5 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

138
total citations
FWCI
42.86
Percentile
100%
References
35
Citations per year

Authors

9

Topics & keywords

Keywords
  • Medicine
  • Semaglutide
  • Prediabetes
  • Placebo
  • Double blind
  • Physical therapy
  • Internal medicine
  • Diabetes mellitus
UN Sustainable Development Goals
  • Zero hunger
No related works found for this paper.

Funding